科伦药业(002422) - 2021 Q4 - 年度财报

Financial Performance - The company's operating revenue for 2021 was CNY 17,277,407,533, representing a 4.94% increase compared to CNY 16,464,201,277 in 2020[21]. - The net profit attributable to shareholders for 2021 was CNY 1,102,554,348, a 32.94% increase from CNY 829,386,336 in 2020[21]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 1,037,613,668, which is a 65.14% increase from CNY 628,321,421 in 2020[21]. - The net cash flow from operating activities for 2021 was CNY 2,847,118,428, up 28.28% from CNY 2,219,381,519 in 2020[21]. - The basic earnings per share for 2021 was CNY 0.78, a 34.48% increase from CNY 0.58 in 2020[21]. - The total assets at the end of 2021 were CNY 31,539,910,785, a decrease of 1.39% from CNY 31,983,345,963 at the end of 2020[21]. - The net assets attributable to shareholders at the end of 2021 were CNY 13,856,827,920, reflecting a 2.65% increase from CNY 13,499,180,423 at the end of 2020[21]. - The gross profit reached 9.617 billion yuan, an increase of 6.86 billion yuan, representing a growth of 7.68% year-on-year[55]. - The company achieved a revenue of 17.277 billion yuan, representing a year-on-year growth of 4.94%, and a net profit of 1.103 billion yuan, up 32.94%[84]. - The company reported a total revenue of 23,801.57 million yuan for the year, with a year-on-year growth of 0.36%[142]. Dividend and Shareholder Information - The company plans to distribute a cash dividend of 4.26 CNY per 10 shares based on a total of 1,406,276,982 shares[4]. - The board of directors has confirmed the accuracy and completeness of the annual report, ensuring no misleading statements or omissions[3]. Research and Development (R&D) - The company has invested over ¥8.5 billion in R&D since 2013, establishing itself as a leader in innovation within the pharmaceutical sector[38]. - The company applied for 351 patents in 2021 and received 195 patent grants, totaling 4,162 applications and 2,258 grants by the end of 2021[57]. - Research and development (R&D) investment amounted to 1.80 billion yuan in 2021, representing an increase of 18.68% compared to 1.52 billion yuan in 2020, with R&D expenses accounting for 10.42% of operating revenue[119]. - The company has initiated research on over 300 drug products, including 276 generics and 63 innovative small molecules and biopharmaceuticals, demonstrating a strong commitment to R&D[60]. - The company is focusing on unmet clinical needs and global pharmaceutical frontiers to accelerate its innovation transformation[59]. Product Development and Innovation - The company launched 33 new products and submitted 30 for production approval in 2021, with a total of 94 products approved since 2017[56]. - The company has developed a total of 598 varieties of pharmaceutical products, including 130 varieties of infusion products and 397 varieties of other dosage forms[42]. - The company has established a product cluster advantage in oncology, parenteral nutrition, bacterial infections, and fluid balance, while expanding into cardiovascular, anesthesia, and diabetes treatment areas[61]. - The approval of iodinated contrast agents and gadobutrol injection signifies the company's entry into large-scale production in the contrast agent product cluster[62]. - The company is advancing several major R&D projects, including KL-A167 injection for nasopharyngeal cancer, with a market application submitted in November 2021[112]. Market and Sales Performance - The company’s antibiotic industry chain has established a comprehensive competitive advantage, addressing environmental issues in antibiotic fermentation[37]. - The company’s international sales revenue reached 897 million yuan, marking a year-on-year increase of 3.70%, despite challenges from the pandemic and rising freight costs[97]. - The company has expanded its marketing network with the establishment of a marketing center and various specialized departments[47]. - The company’s core product in the parenteral nutrition field saw a sales increase of 12.72% in 2021[92]. - The company is focused on optimizing its internal incentive mechanisms and expanding new business models to improve operational quality amid market uncertainties[84]. Risk Management - The company faces various risks including industry policy changes, market risks, and R&D innovation risks, which investors should be aware of[4]. - The company has implemented a foreign exchange hedging strategy to mitigate risks associated with currency fluctuations[143]. - The company emphasizes compliance and risk management in its foreign exchange hedging operations, ensuring that transactions are conducted with qualified financial institutions[143]. Corporate Governance - The company has a governance structure that complies with relevant laws and regulations, ensuring equal rights for all shareholders, especially minority shareholders[173]. - The board of directors consists of 9 members, including 3 independent directors, and has established several specialized committees to provide professional advice for decision-making[175]. - The company has established a comprehensive supply, research and development, production, and sales system, demonstrating its ability to operate independently in the market[182]. Environmental and Social Responsibility - The company actively promotes environmental management and energy management system certifications to lead in clean and efficient pharmaceutical production[45]. - The company has established a robust framework for social responsibility and actively participates in public welfare and charity initiatives[177]. - The company is committed to environmental management and aims to achieve dual control of energy consumption and carbon emissions through various initiatives[160]. Future Outlook - The company plans to continue its "three-driving force, innovation growth" strategy to maintain its leading position in the infusion field and enhance its competitive advantage in the antibiotic industry chain[150]. - Future guidance indicates a positive outlook, with expectations for continued revenue growth driven by market expansion strategies and potential acquisitions[192]. - The company aims to enhance its R&D efficiency by introducing high-level talent and fostering external innovation collaborations[58].